Dry eye disease management increasingly relies on a nuanced understanding of artificial tear composition, beyond symptomatic relief alone. Marketed formulations differ significantly in their active demulcents and biologically active excipients, which influence hydration, tear film stability, and epithelial protection.
Ingredient-driven classification and selection enable a more rational, stepwise approach to therapy, while emerging evidence highlights the added benefits of dual-polymer systems in enhancing ocular surface protection and recovery.1,2 Take a moment—just 2 minutes—to test your understanding of ingredient-based artificial tear selection and its clinical implications.